Whitehawk Therapeutics, Inc. · NASDAQ:WHWK

Whitehawk Therapeutics — Investor Presentation (August 2026)

36 slides from Whitehawk Therapeutics's investor presentation, August 2026

  1. Slide 1: Corporate Presentation August 2026

    Corporate Presentation August 2026

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, kn

  3. Slide 3: Why Whitehawk

    Why Whitehawk Differentiated Approach, Pipeline Momentum & Execution Focus Differentiated • Whitehawk ADC platform built on CPT113 linker payload + CBCR bioconjugation process Science • Validated but not inundated targets: PTK7, MUC16, SEZ6 Multiple Shots • HWK-007, HWK-016 in Ph1 + HWK-206 on track

  4. Slide 4: ADC Portfolio Overview

    ADC Portfolio Overview Three Near-Term ADC Programs Targeting High-Potential Indications HWK-007 HWK-016 HWK-206 Target Antigen: PTK7 Target Antigen: MUC16 Target Antigen: SEZ6 • Present in ~70% of solid tumors with • “Super expressed” in gynecological cancers • SEZ6 is the highest expressed SCLC an

  5. Slide 5: Whitehawk ADC Platform

    Whitehawk ADC Platform Optimized Next-Generation ADC Platform Designed for Differentiation Whitehawk ADC • High affinity antibody selection 1 Targeting Novel TOP1i Carbon bridge • Attenuated Fc region (CPT116), DAR6 • Carbon bridge cysteine re-pairing 2 Bioconjugation • Optimized DAR6 configuration

  6. Slide 6: Validating Clinical Data for CPT113 from Partner

    Validating Clinical Data for CPT113 from Partner Hangzhou DAC Program Shows Promising Efficacy & Tolerability DXC006: Hangzhou DAC’s CD56-directed ADC Utilizes Same Linker-Payload as Whitehawk Promising efficacy signal in SCLC and NSCLC Promising tolerability with limited heme toxicity Source: ASCO

  7. Slide 7: Collaborations Support Future Pipeline Growth

    Collaborations Support Future Pipeline Growth Ambition to Deliver New ADC INDs in Next 12-24 Months Linker-Payload (CPT113) Bispecific Antibodies Access to Hangzhou DAC’s CPT113 linker- Global collaboration with Biocytogen for payload for use in up to 5 new Carbon access to up to 5 bispecific antibo

  8. Slide 8: Whitehawk Programs Advancing in the Clinic

    Whitehawk Programs Advancing in the Clinic Phase 1 Trials Started Above Anticipated Minimally Effective Dose HWK-007 Ph1a Dose Escalation & Backfill (N≤66)* HWK-016 Ph1a Part A Dose Escalation & Backfill (N≤75)** BOIN Design BOIN Design Potential Potential 8 mg/kg Backfill 10 mg/kg Backfill Potentia

  9. Slide 9: Near-Term Pipeline Milestones

    Near-Term Pipeline Milestones Multiple Clinical Shots on Goal; Pipeline Expansion Entering Clinic in 12-24 Months​ Stage Anticipated Asset Target Payload Candidate Indications Upcoming IND-enabling Phase I Milestones selection • NSCLC HWK-007 PTK7 Top1i • Ovarian Data 1H 2027 • Endometrial • Ovarian

  10. Slide 10: Expected Near-Term Milestones

    Expected Near-Term Milestones Advancing Our Focused Pipeline Toward Multiple Inflection Points 2026 2027-2028 May 2026 Q3 2026 1H 2027 IND Filings for New Assets New HWK-206 HWK-007 & 2H ‘27 / Option Study HWK-016 1H ’28 Agreement Initiation Clinical Data 10

  11. Slide 11: Assets

    Assets 11

  12. Slide 12: HWK-007

    HWK-007 12

  13. Slide 13: PTK7 is A Broadly Expressed, Clinically Relevant Tumor Target

    PTK7 is A Broadly Expressed, Clinically Relevant Tumor Target Present in ~70% of solid tumors with Third most highly expressed high proportion of mod/high expression tumor marker1 7.6 Skin cancer–non-melanocytic (n=573) 7.6 Uterine cancer (n=703) 7.4 7.0 Endometrial cancer (n=4349) HER3 7.4 6.9 Vulv

  14. Slide 14: PTK7 Tumor Target Clinically Validated by Pfizer 1st Generation ADC

    PTK7 Tumor Target Clinically Validated by Pfizer 1st Generation ADC Cofe-P ORR from FIH Q3W Cohorts1 46% ORR Range in Q3W Cohorts: 27% 25% 23% 21% 16% • 16-27% in all patients • 23-46% in PTK7 moderate-high subgroup PROC (n=44) NSCLC (n=25) TNBC (n=29) ORR (all evaluable) ORR PTK7 (mod/high) • Dose-

  15. Slide 15: HWK-007 Structure and Mechanism of Action

    HWK-007 Structure and Mechanism of Action 15

  16. Slide 16: HWK-007 Designed to Optimize Performance vs Other PTK7 ADCs

    HWK-007 Designed to Optimize Performance vs Other PTK7 ADCs Program SKB518 DAY301 LY4175408 KIVU-107 HWK-007 Potential HWK-007 (Platform, Company) (OptiDC, Kelun) (T1000, DayOne) (PSARLink, Lilly) (Synaffix, Kivu) (CBCR, Whitehawk) advantage Fc Region Attenuated Silenced Attenuated Wildtype Wildtype

  17. Slide 17: HWK-007 Demonstrates Efficient PTK7 Engagement and a Favorable Translational Profile

    HWK-007 Demonstrates Efficient PTK7 Engagement and a Favorable Translational Profile Potent PTK7 Binding Potent Anti-Tumor Activity Exceptional Stability & Favorable PK and Internalization • High affinity PTK7 binding with slow off-rate and • Deep responses observed at doses as low as 1 • Very high

  18. Slide 18: Clinical Status of Current PTK7 ADCs, No Clinical Data Reported to Date

    Clinical Status of Current PTK7 ADCs, No Clinical Data Reported to Date SKB518 DAY301 LY4175408 KIVU-107 HWK-007 IDE-034 OptiDC CBCR Platform T1000 PSARLink Synaffix RenLite TMT (CPT113) Ph 1 Status Ph 2 (NSCLC) Ph 1 Ph 1 Ph 1 Ph 1 Ph 1 China Only US, China, France, Regions China US, Canada Japan, S

  19. Slide 19: HWK-007-101 FIH Phase 1 Dose Escalation and Expansion Study

    HWK-007-101 FIH Phase 1 Open-label Dose Escalation and Dose Expansion Study of HWK-007 Monotherapy Phase 1b Dose Expansion Screening Phase 1a Dose Escalation & Backfill (N≤66)** (N≤160) • Patients with advanced metastatic BOIN Design Dose Optimization non-squamous EGFR WT NSCLC, PROC and endometrial

  20. Slide 20: HWK-016

    ice) 9 Nz = T 20

  21. Slide 21: MUC16 is Super Expressed, Stable and Clinically Relevant Tumor Target

    MUC16 is “Super Expressed,” Stable and Clinically Relevant Tumor Target for Gynecological Cancers MUC16 is the highest-expressing ADC MUC16 is highly expressed in the most aggressive target in ovarian cancer and most common endometrial cancer subtypes MUC16 mRNA Expression Relative to Other Therapeu

  22. Slide 22: MUC16 Clinical Precedent from Discontinued Genentech 1st Gen ADC

    MUC16 Clinical Precedent from Discontinued Genentech 1st Gen ADC DMUC4064A ORR by dose cohort Saturated levels of 42% ORR at RP2D circulating CA125 42% Binding to circulating CA125 may 29% have hindered DMUC4064A 17% effectiveness 0% 0% 0% 0% mg/kg 1 1.8 2.4 3.2 4.0 4.8 5.2 N= 3 3 8 7 6 7 26 • Ocula

  23. Slide 23: HWK-016 Structure and Mechanism of Action

    HWK-016 Structure and Mechanism of Action 23

  24. Slide 24: HWK-016 Targets Membrane-Bound MUC16 to Mitigate Shedding Effects

    HWK-016 Targets Membrane-Bound MUC16 to Mitigate Shedding Effects and Drives Robust Tumor Regression Membrane-bound MUC16 Targeting Binding Advantage Translates Exceptional Stability Enables Durable Tumor Engagement IntoInto Potent Anti-Tumor Potent Activity Tumor Killing & Favorable PK • High-affin

  25. Slide 25: HWK-016-101 FIH Phase 1 Dose Escalation and Expansion Study

    HWK-016-101 FIH Phase 1 Open-label Dose Escalation and Dose Expansion Study of Monotherapy and Combination with Bevacizumab Ph1b Part A Dose Expansion Screening Ph1a Part A Dose Escalation & Backfill (N≤75)* (N=120) • Patients with advanced or BOIN Design Dose Optimization MONOTHERAPY metastatic PRO

  26. Slide 26: Beyond Gynecological Cancers, MUC16 Indications Could Drive Further Expansion

    Beyond Gynecological Cancers, MUC16 Biomarker-Selected Indications Could Drive Further Expansion Proportion with high expression* Ovarian, Fallopian Tube & 9.0 87% Primary Peritoneal cancer (n = 7244) Uterine cancer 7.0 73% (n = 5052) Given strong, bimodal expression, Mesothelioma 6.5 68% mesothelio

  27. Slide 27: HWK-206

    HWK-206 27

  28. Slide 28: SEZ6 is the Highest Expressed SCLC Antigen

    SEZ6 is the Highest Expressed SCLC Antigen; Overexpressed in Other Neuroendocrine Neoplasms and CNS Tumors SEZ6 expression across tumor types1 Antigen Expression in SCLC (SEER 2024 Annual US Incidence) Lung Small Cell Carcinoma (N = 2098) SCLC 6.5 (35,000) SEZ6 5.1 B7-H3 NETs 5.0 (31,000) DLL3 3.4 T

  29. Slide 29: AbbVie Next Wave ADC ABBV-706 SCLC Efficacy in Ongoing Ph1

    AbbVie Next Wave ADC ABBV-706 SCLC Efficacy in Ongoing Ph1 59% ORR in SCLC (23/39) at 2.5 mg/kg AbbVie reported “promising efficacy and manageable safety” of ABBV-706 monotherapy in patients with relapsed/refractory SCLC Byers et al, World Conference on Lung Cancer (WCLC), September 6-9, 2025. 29

  30. Slide 30: Biparatopic Approach May Provide Path to Greater Gains

    Despite Improvements Seen With Next Wave SCLC ADCs, a Biparatopic Approach May Provide Path to Greater Gains HWK-206: A biparatopic ADC 30

  31. Slide 31: HWK-206 is SEZ6-Targeted TOP1 ADC with Superior Target Engagement

    HWK-206 is SEZ6-Targeted TOP1 ADC with Superior Target Engagement, Potent Antitumor Activity and Platform-Consistent Stability Potent SEZ6 Binding and Internalization Potent Anti-Tumor Activity with Exceptional Stability Across Expression Levels Comparable Efficacy vs ABBV-706 & Favorable PK • Demon

  32. Slide 32: Questions

    Questions 32

  33. Slide 33: Appendix

    Appendix 33

  34. Slide 34: Whitehawk Improvements to CPT113

    Whitehawk Improvements to CPT113 Proprietary CBCR Process Increases DAR and Improves Key Nonclinical Measures vs DXC006 CPT113 + v1.0 Carbon Bridge Whitehawk’s Bioconjugation Cysteine Re-pairing ADC Platform (Hangzhou DAC, JNJ) (CBCR) Process DXC006 Unique manufacturing HWK-007, HWK-016, HWK-206 IP

  35. Slide 35: Switching from Tubulin Inhibitor to Top1i-based ADCs Delivers ORR Improvement

    Switching from Tubulin Inhibitor to Top1i-based ADCs on Same Target Delivers 15-45pt ORR Improvement in Phase 1 Studies ADC Target Indication Program Payload, DAR ORR1 (%) ORR Gain (Pts) SGNB7H4 MMAE, 2 25 B7-H4 TNBC +16 HS20089 TOPO1, 8 41 Teliso-V+ MMAE, 2 35 cMET NSCLC +16 Temab-A+ TOPO1, 6 51 El

  36. Slide 36: Whitehawk Improvements to CPT113

    Whitehawk Improvements to CPT113 Whitehawk’s CBCR ADCs Demonstrate Potential Class-Leading Payload Stability Free Payload vs ADC in Circulation1 Approved Top1i ADCs % Molar ratio of free payload / ADC (AUC) (Dxd platform) show 1 ~0.1% free payload in circulation 15X more 0.1 stable Improvements in s

Whitehawk Therapeutics — Investor Presentation (August 2026) on 6ix